Display options
Cite
Olschewski H, Rich S. Are anticoagulants still indicated in pulmonary arterial hypertension?. Pulm Circ. 2018;8(4):2045894018807681doi: 10.1177/2045894018807681.
Olschewski, H., & Rich, S. (2018). Are anticoagulants still indicated in pulmonary arterial hypertension?. Pulmonary circulation, 8(4), 2045894018807681. https://doi.org/10.1177/2045894018807681
Olschewski, Horst, and Rich, Stuart. "Are anticoagulants still indicated in pulmonary arterial hypertension?." Pulmonary circulation vol. 8,4 (2018): 2045894018807681. doi: https://doi.org/10.1177/2045894018807681
Olschewski H, Rich S. Are anticoagulants still indicated in pulmonary arterial hypertension?. Pulm Circ. 2018 Oct-Dec;8(4):2045894018807681. doi: 10.1177/2045894018807681. Epub 2018 Oct 04. PMID: 30284508; PMCID: PMC6202749.
Copy Download .nbib Format: NLM
Share it on

Pulm Circ. 2018 Oct-Dec;8(4):2045894018807681. doi: 10.1177/2045894018807681. Epub 2018 Oct 04.

Are anticoagulants still indicated in pulmonary arterial hypertension?.

Pulmonary circulation

Horst Olschewski, Stuart Rich

Affiliations

  1. 1 Klinische Abteilung für Lungenkrankheiten LKH Universitätsklinik / Med. Universität, Division of Pulmonology?-?Department of Internal Medicine, Graz, Austria.
  2. 2 Northwestern University Feinberg School of Medicine, Pulmonary Vascular Disease Program, Bluhm Cardiovascular Institute, Chicago, IL, USA.

PMID: 30284508 PMCID: PMC6202749 DOI: 10.1177/2045894018807681

Abstract

Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that is a progressive, fatal disease. Multiple underlying mechanisms for PAH have been identified, including vasoconstriction, intimal proliferation, medial hypertrophy, inflammation, mitochondrial dysfunction, and in situ thrombosis. Because it is an uncommon disease, it has been challenging to identify a specific treatment that targets the dominant disease mechanism in a given patient. Early success demonstrating that some patients (approximately 10%) possess pulmonary vasoreactivity at diagnosis has driven the development of pulmonary vasodilators as the mainstay of treatment. However, while they improve exercise tolerance in clinical trials, their effect on survival is limited. Therapies that target underlying disease mechanisms that affect a majority of patients are clearly needed if we are to significantly improve overall survival. In the actual guidelines, chronic anticoagulation is no longer recommended in patients with idiopathic, hereditary, and drug-induced PAH although there is much indirect evidence for this. There are data from over 40 years which include: (1) pathology studies showing the presence of thrombotic lesions in a majority of patients with PAH, both idiopathic and associated with many other conditions; (2) a similar frequency of thrombotic lesions in patients treated with pulmonary vasodilators as was seen in the years before their use; (3) mechanistic studies showing that procoagulant conditions predispose to the development of intraluminal thrombosis that contributes to vascular remodeling and the progressive nature of the pathologic changes; and (4) observational studies that, with one exception, have demonstrated a substantial survival advantage in patients with PAH treated with oral anticoagulation. Acknowledging that no prospective randomized trial with anticoagulants has ever been done, we recommend a pragmatic approach to the use of anticoagulants in PAH. We suggest that the risks and benefits of chronic anticoagulation be considered in individual patients, and that warfarin be prescribed in patients with PAH, unless they have an increased risk of bleeding. The question of whether direct oral anticoagulants (DOACs) would provide the same benefit as vitamin K antagonists is valid, but presently there are no data at all regarding their use in PAH. However, in patients with PAH in whom warfarin anticoagulation management proves problematic, it is reasonable to switch the patient to a DOAC as is current practice for other conditions.

Keywords: anticoagulants; inflammation; pulmonary arterial hypertension; thrombosis

References

  1. Circulation. 2014 Jan 7;129(1):57-65 - PubMed
  2. J Biol Chem. 1992 Oct 15;267(29):20831-4 - PubMed
  3. Int J Cardiol. 2018 Nov 15;271:219-227 - PubMed
  4. N Engl J Med. 1992 Jul 9;327(2):76-81 - PubMed
  5. Carbohydr Res. 2002 Nov 19;337(21-23):2359-64 - PubMed
  6. Curr Opin Cell Biol. 1999 Apr;11(2):219-25 - PubMed
  7. Clin Cardiol. 1996 Jul;19(7):549-54 - PubMed
  8. Circulation. 2015 Dec 22;132(25):2403-11 - PubMed
  9. Circulation. 1990 Sep;82(3):841-7 - PubMed
  10. Circulation. 2007 Nov 13;116(20):2298-306 - PubMed
  11. Chest. 1997 Sep;112(3):714-21 - PubMed
  12. Am J Respir Crit Care Med. 2012 Aug 1;186(3):261-72 - PubMed
  13. Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):504-8 - PubMed
  14. FASEB J. 2012 Nov;26(11):4540-7 - PubMed
  15. Nature. 2000 Sep 14;407(6801):258-64 - PubMed
  16. Physiol Rep. 2013 Dec 29;1(7):e00190 - PubMed
  17. Am J Respir Crit Care Med. 2015 Jan 15;191(2):208-18 - PubMed
  18. Science. 1998 Jun 26;280(5372):2109-11 - PubMed
  19. Annu Rev Pharmacol Toxicol. 1997;37:167-203 - PubMed
  20. Chest. 1996 Sep;110(3):710-7 - PubMed
  21. Circulation. 1984 Oct;70(4):580-7 - PubMed
  22. Circulation. 1989 Nov;80(5):1198-206 - PubMed
  23. Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1577-86 - PubMed
  24. Mol Pharmacol. 2005 Jan;67(1):2-11 - PubMed
  25. Am Rev Respir Dis. 1992 Jan;145(1):193-6 - PubMed
  26. Am J Physiol Lung Cell Mol Physiol. 2015 May 15;308(10):L1002-13 - PubMed
  27. Science. 1997 Jan 24;275(5299):533-6 - PubMed
  28. Eur Respir J. 1996 Feb;9(2):356-63 - PubMed
  29. Nature. 1991 Apr 11;350(6318):516-8 - PubMed
  30. Am J Respir Crit Care Med. 1994 Oct;150(4):929-33 - PubMed
  31. Z Kardiol. 1993 Sep;82(9):568-72 - PubMed

Publication Types